A New Take on Preclinical Drug Trials for Glioblastoma Treatment
The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512